Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 15:7:463.
doi: 10.3389/fped.2019.00463. eCollection 2019.

Targeted Therapies for Pediatric AML: Gaps and Perspective

Annalisa Lonetti  1 , Andrea Pession  1   2 , Riccardo Masetti  2
Affiliations
Review

Targeted Therapies for Pediatric AML: Gaps and Perspective

Annalisa Lonetti et al. Front Pediatr. .

Abstract

Acute myeloid leukemia (AML) is a hematopoietic disorder characterized by numerous cytogenetic and molecular aberrations that accounts for ~25% of childhood leukemia diagnoses. The outcome of children with AML has increased remarkably over the past 30 years, with current survival rates up to 70%, mainly due to intensification of standard chemotherapy and improvements in risk classification, supportive care, and minimal residual disease monitoring. However, childhood AML prognosis remains unfavorable and relapse rates are still around 30%. Therefore, novel therapeutic approaches are needed to increase the cure rate. In AML, the presence of gene mutations and rearrangements prompted the identification of effective targeted molecular strategies, including kinase inhibitors, cell pathway inhibitors, and epigenetic modulators. This review will discuss several new drugs that recently received US Food and Drug Administration approval for AML treatment and promising strategies to treat childhood AML, including FLT3 inhibitors, epigenetic modulators, and Hedgehog pathway inhibitors.

Keywords: DOT1L inhibitors; FLT-3 inhibitors; Hedgehog pathway inhibitors; Pediatric AML; targeted therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cooperation between oncogenic signaling pathways in pediatric AML. Schematic representation of deregulated signaling and mutated proteins, involved in AML cell proliferation and survival, that can be targeted in pediatric patients. HH, hedgehog; RTK, receptor tyrosine kinase.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R, et al. . Collaborative efforts driving progress in pediatric acute myeloid leukemia. J Clin Oncol. (2015) 33:2949–62. 10.1200/JCO.2015.62.8289 - DOI - PMC - PubMed
    1. Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. (2012) 119:34–43. 10.1182/blood-2011-04-347872 - DOI - PMC - PubMed
    1. Masetti R, Vendemini F, Zama D, Biagi C, Pession A, Locatelli F. Acute myeloid leukemia in infants: biology and treatment. Front Pediatr. (2015) 3:37. 10.3389/fped.2015.00037 - DOI - PMC - PubMed
    1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. (2016) 127:2391–405. 10.1182/blood-2016-03-643544 - DOI - PubMed
    1. Sandahl JD, Kjeldsen E, Abrahamsson J, Ha SY, Heldrup J, Jahnukainen K, et al. . The applicability of the WHO classification in paediatric AML. A NOPHO-AML study Br J Haematol. (2015) 169:859–67. 10.1111/bjh.13366 - DOI - PubMed